This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's Stop Trading: Buy GW Pharmaceuticals, Not ConAgra Foods

NEW YORK (TheStreet) -- After rallying higher on Tuesday following positive reports about its cannabinoid epilepsy drug, Epidiolex, shares of GW Pharmaceuticals (GWPH) are lower by roughly 5% on Wednesday after the company announced a secondary offering. 

On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said investors want to buy the stock on its secondary offering. 

Why? Well, it's simple. Cramer reasoned that GW Pharmaceuticals is the "only really legitimate" marijuana company for investors to put their money in. The British company is also doing very well, he added. 

However, he did not feel the same toward ConAgra Foods (CAG - Get Report), which reported "a horrible quarter."

According to the CEO, the dividend is still safe, Cramer said. But its private label brands are doing "poorly," consumer volume was weak, and the numbers for Chef Boyardee were "terrible." 

He concluded that canned foods are simply not selling well, because they do not give off the impression of natural and organic food.

-- Written by Bret Kenwell in Petoskey, Mich.

15 Minutes of Every Hour Meeting Are a Waste of Time

Apple Unveils Latest iMac, Starting at $1,099

The U.K. Is 'Pound'-ing the Pavement With Chinese Business Deals

Citigroup Looks Like a Smart Hedge as Interest Rates Remain Low

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CAG $36.76 0.00%
GWPH $88.26 2.10%
AAPL $125.62 1.90%
FB $83.17 -0.16%
GOOG $552.39 0.74%


DOW 18,001.03 +288.37 1.63%
S&P 500 2,084.98 +23.96 1.16%
NASDAQ 4,939.14 +47.9210 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs